TLK1-IN-1
TLK1-IN-1 is a TLK1B inhibitor with a human IC50 of 7.2 μM. TLK1-IN-1 causes accumulation of DNA damage and induces apoptotic cell death in cancer cells. TLK1-IN-1 can be used for the research of metastatic castration-resistant prostate cancer.
For research use only. We do not sell to patients.
- Formula: C24H23BrClN5O3
- Molecular Weight:544.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
TLK1B 7.2 μM (IC50) |
In Vitro
TLK1-IN-1 (Compound 5n) potently inhibits recombinant TLK1B activity with an IC50 of 7.2 μM using the Nek1 peptide substrate[1].
TLK1-IN-1 (72 小时) is selectively cytotoxic to LNCaP and DU145 prostate cancer cells with GI50 values of 2.7 μM and 6.5 μM, respectively, while showing low toxicity to non-cancerous HEK293 cells[1].
TLK1-IN-1 (5 μM; 72 h) potently suppresses colony formation by LNCaP cells[1].
TLK1-IN-1 (0.2-5 μM; 48 h) inhibits the TLK1 pathway in LNCaP cells, showing dose-dependent inhibition at sub-micromolar concentrations (0.2-1.6 μM)[1].
TLK1-IN-1 (0.5 μM; 36-48 h) plus Bicalutamide (HY-14249) induces DNA damage and apoptosis in LNCaP cells, while TLK1-IN-1 alone increases pro-apoptotic BAX levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LNCaP cells
-
Concentration:5 μM
-
Incubation Time:72 h
-
Result:Reduced colony formation by LNCaP cells by 4-fold compared to the positive control.
Resulted in the lowest normalized colony number among tested compounds.
-
Cell Line:LNCaP cells
-
Concentration:0.2 μM; 0.4 μM; 0.6 μM; 0,8 μM; 1.6 μM; 5 μM
-
Incubation Time:48 h
-
Result:Reduced pRad9-S328 levels.
Showed a dose-dependent reduction in pRad9-S328 levels at sub-micromolar concentrations (0.2-1.6 μM).
-
Cell Line:LNCaP cells
-
Concentration:0.5 μM; 0.5 μM plus Bicalutamide (5 μM)
-
Incubation Time:48 h
-
Result:Increased pH2AX levels by ~4-fold compared to control when combined with 5 μM Bicalutamide.
Increased pro-apoptotic BAX levels by 4-fold compared to control when combined with 5 μM Bicalutamide.
Reduced anti-apoptotic Bcl-2 levels by 6-fold compared to control when combined with 5 μM Bicalutamide.
Increased BAX levels by 2.5-fold compared to control when used alone at 0.5 μM.
Chemical Information
-
Molecular Weight 544.83
-
Formula C24H23BrClN5O3
-
SMILES
O=C(NC1=CC=C(Cl)C=C1)CN(N=C2)C(C3=C2C4=CC(Br)=CC=C4N3CCN5CCOCC5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)